Amicus Therapeutics to Present at Leerink Swann Rare Disease Roundtable

Amicus Therapeutics to Present at Leerink Swann Rare Disease Roundtable

CRANBURY, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief
Executive Officer, will present a corporate overview at the Leerink Swann Rare
Disease Roundtable in New York, NY on Wednesday, October 2, 2013 at 1:20 p.m.
ET.

A live webcast of the presentation can be accessed through the Investors
section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.


About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe
disease.

FOLD-G

CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
         spellegrino@amicusrx.com
 
Press spacebar to pause and continue. Press esc to stop.